Results 91 to 100 of about 27,203 (237)

Drug‐Induced Renal Vasculitis: Etiology, Pathogenesis, Clinical Manifestations, and Therapeutic Approaches—A Narrative Review

open access: yesHealth Science Reports, Volume 8, Issue 4, April 2025.
ABSTRACT Background and Aims Drug‐induced renal vasculitis arises from various medications that cause immunological dysregulation or direct vascular damage, leading to inflammation and thrombosis. Clinical manifestations vary widely, from mild constitutional symptoms to severe organ dysfunction. This review aims to thoroughly explore drug‐induced renal
Hashim Mohamed Siraj   +7 more
wiley   +1 more source

Anti‐NMDA receptor autoimmune encephalitis associated with ovarian teratoma: A case series and literature review

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 169, Issue 1, Page 23-30, April 2025.
Abstract Autoimmune encephalitis is a group of disorders characterized by symptoms of dysfunction of the limbic and extra‐limbic systems that occur in association with antibodies against intracellular antigens, synapses, or proteins located on the surface of nerve cells. Anti‐NMDA (N‐methyl‐D‐aspartate) receptor encephalitis was first described in 2007
Pham Ba Nha   +6 more
wiley   +1 more source

Combined Treatment With Lipoprotein Apheresis and Hemodialysis in Patients With Severe Cardiovascular Disease, High Lipoprotein(a) and End Stage Renal Disease

open access: yesJournal of Clinical Apheresis, Volume 40, Issue 2, April 2025.
ABSTRACT Elevated Lipoprotein(a) (Lp(a)) is a known independent cardiovascular risk factor. Lp(a) Lipoprotein Apheresis (LA) substantially reduces the number of cardiovascular events. The effect of LA treatment in hemodialysis (HD) patients remains unknown. Retrospective analysis of nine patients undergoing LA and HD.
Tilmann Röseler   +3 more
wiley   +1 more source

Plasmapheresis: a rational treatment for fulminant acute pancreatitis? [PDF]

open access: bronze, 1988
Mike Larvin   +5 more
openalex   +1 more source

Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real‐World Analysis

open access: yeseJHaem, Volume 6, Issue 2, April 2025.
ABSTRACT Introduction We retrospectively analysed bortezomib–dexamethasone–rituximab (BDR) combination in patients with Waldenström macroglobulinaemia (WM) in a real world setting. Methods A total of 87 patients were included: 49 patients (56%) were treated in frontline, 22 (25%) in second line and 16 (19%) in third or further line settings. A log‐rank
Thomas Hueso   +14 more
wiley   +1 more source

Exploring Cryoglobulinemia's Clinical Odyssey: A Case Series

open access: yeseJHaem, Volume 6, Issue 2, April 2025.
ABSTRACT Cryoglobulinemia (CG) encompasses disorders in which immunoglobulins precipitate at low temperatures. According to Brouet's classification, Type I CG is linked to plasma cell disorders, while mixed CG (Types II and III) is associated with autoimmune conditions, infections (notably hepatitis C virus [HCV]), and lymphoproliferative disorders ...
Shivangini Duggal   +5 more
wiley   +1 more source

Multifocal Motor Neuropathy: A Narrative Review

open access: yesMuscle &Nerve, Volume 71, Issue 4, Page 512-534, April 2025.
ABSTRACT Multifocal motor neuropathy (MMN) is an acquired autoimmune polyneuropathy that affects almost exclusively the motor nerve fibers. Typically seen in middle‐aged adults, its predominant clinical feature is a chronically progressive asymmetric weakness that affects the distal upper extremities most significantly.
Benjamin Claytor   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy